. 2019 Apr;8(2):135–143. doi: 10.21037/tlcr.2019.03.10

Table 2. Validation using NGS in patients with inconsistent gene regions mutation in the paired plasma and tissue samples by ADx-ARMS.

No.	ARMS in plasma	ARMS in tumor tissue	NGS in plasma
No.	ARMS in plasma	ARMS in tumor tissue	Mutant-type	Abundance (%)
1	19-Del	19-Del/T790M	19-Del^†	1.26
1	19-Del	19-Del/T790M	T790M	2.20
2	L858R	L858R/T790M	L858R	0.48
2	L858R	L858R/T790M	T790M	0.27
3	L858R	L858R/T790M	L858R	15.37
3	L858R	L858R/T790M	T790M	1.61
4	19-Del	Wild-type	19-Del^‡	9.45

^†, L747_T751del; ^‡, E746_A750del. ADx-ARMS, ADx-Amplification Refractory Mutation System; NGS, next-generation sequencing; 19-Del, exon 19 deletion.